Vancouver-based biotech companies Gandeeva Therapeutics and Zymeworks have partnered to generate cryo-EM–based structural data to augment antibody drug discovery.

总部位于温哥华的生物技术公司Gandeeva Therapeutics和Zymeworks已达成合作，生成基于冷冻电镜的结构数据，以增强抗体药物发现。

VANCOUVER, BC

温哥华，不列颠哥伦比亚省

,

，

June 18, 2026

2026年6月18日

/PRNewswire/ - Gandeeva Therapeutics, Inc., a biotech at the forefront of cryo-electron microscopy (cryo-EM)

/美通社/ - Gandeeva Therapeutics, Inc.，一家处于冷冻电子显微镜（cryo-EM）前沿的生物科技公司

–

–

driven drug design, and Zymeworks Inc. (Nasdaq:

驱动的药物设计，以及 Zymeworks 公司（纳斯达克：

ZYME

酶

), a global biotechnology company, have partnered to visualize structures of antibody-antigen interfaces at high resolution.

），一家全球生物技术公司，已合作以高分辨率可视化抗体-抗原界面的结构。

Continue Reading

继续阅读

2.6 Å cryo-EM structure of antigen-antibody complex with the antigen shown in pink

抗原-抗体复合物的2.6 Å冷冻电镜结构，其中抗原以粉色显示

Representative region of the density map

密度图的代表性区域

While cryo-EM is now used routinely to determine structures of antibody complexes formed with compact and well-folded antigens, mapping antibody epitope footprints on small and flexible antigens remains highly challenging. In a new advance, Gandeeva scientists have determined the structure of a small and flexible antigen (< 20 kDa) bound to the Fab fragment of an antibody developed at Zymeworks.

尽管冷冻电镜（cryo-EM）现已常规用于确定与紧凑且折叠良好的抗原形成的抗体复合物的结构，但在小而灵活的抗原上绘制抗体表位足迹仍然极具挑战性。在一项最新进展中，Gandeeva 的科学家确定了由 Zymeworks 开发的抗体的 Fab 片段与一个小而灵活的抗原（< 20 kDa）结合的结构。

Of note, the team was able to visualize the nine amino acids that form the antibody-binding epitope at 2.6 Å resolution. The rest of the antigen is highly flexible and was not resolved in the reconstruction..

值得注意的是，该团队能够以2.6埃的分辨率可视化构成抗体结合表位的九个氨基酸。抗原的其余部分高度灵活，在重建结构中未能解析。

'Knowledge of the precise interactions at the binding interface of these types of challenging targets is incredibly useful for us in selecting antibody leads and provides us with crucial insights for the optimization of biologics', said Dr. Paul Moore, Chief Scientific Officer of Zymeworks.

Zymeworks首席科学官Paul Moore博士表示：“了解这些具有挑战性的靶点在结合界面处的精确相互作用，对于我们选择抗体先导化合物极为有用，并为生物药的优化提供了关键见解。”

'Our ability to obtain near-atomic resolution cryo-EM structures of the antibody binding epitope within flexible and structurally intractable proteins is a game-changer, especially in the context of accelerating design of AI-driven antibodies', said Dr. Sriram Subramaniam, Founder and CEO of Gandeeva Therapeutics.

“我们能够在柔性且结构复杂的蛋白质中，获得抗体结合表位的近原子分辨率冷冻电镜结构，这是一项颠覆性的突破，尤其在加速人工智能驱动抗体设计的背景下更是如此。”Gandeeva Therapeutics 创始人兼首席执行官 Sriram Subramaniam 博士表示。

'Experimental validation by high-resolution and high-throughput cryo-EM using Gandeeva's platform provides exactly the kind of rapid feedback that is essential for testing and validating antibodies derived by immunization and by computational design.'.

利用Gandeeva平台进行的高分辨率、高通量冷冻电镜实验验证，提供了对通过免疫接种和计算设计获得的抗体进行测试与验证所必需的关键快速反馈。

About Gandeeva

关于甘迪瓦

Gandeeva Therapeutics is a drug discovery company leveraging cryo-EM to advance the development of precision medicines. Headquartered in Vancouver, Canada, Gandeeva operates from a purpose-built facility equipped with state-of-the-art cryo-EM instrumentation. Founded by Dr. Sriram Subramaniam, a global expert in structural biology, Gandeeva's mission is to uncover atomic-level insights into protein-drug interactions and accelerate therapeutic development for challenging diseases.

Gandeeva Therapeutics 是一家利用冷冻电子显微镜（cryo-EM）技术推进精准药物开发的药物发现公司。公司总部位于加拿大温哥华，在专为冷冻电镜研究打造的设施中运营，配备最先进的冷冻电镜仪器。Gandeeva 由结构生物学全球专家 Sriram Subramaniam 博士创立，其使命是揭示蛋白质与药物相互作用的原子级细节，加速针对疑难疾病的治疗开发。

Its proprietary platform streamlines structure-to-drug workflows, enabling rapid, iterative analysis of complex biological targets, including transient protein interfaces and membrane proteins. By integrating high-resolution imaging with advanced machine learning, Gandeeva supports the design of molecular glues, engineered antibodies, and small molecules to modulate protein function with precision and efficacy.

其专有平台优化了从结构到药物的工作流程，实现了对复杂生物靶点（包括瞬时蛋白质界面和膜蛋白）的快速迭代分析。通过将高分辨率成像与先进的机器学习相结合，Gandeeva 支持分子胶、工程化抗体和小分子的设计，以精准高效地调节蛋白质功能。

Gandeeva applies its platform to its own drug development and partners with other biotechnology and pharma companies to accelerate their drug development programs..

Gandeeva将其平台应用于自身的药物研发，并与其他生物技术和制药公司合作，以加速他们的药物研发项目。

For more information, visit

更多信息，请访问

www.gandeeva.com

www.gandeeva.com

or follow on

或关注

LinkedIn

领英

and @Gandeeva_Tx on X.

以及 X 上的 @Gandeeva_Tx。

About Zymeworks

关于 Zymeworks

Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease. Zymeworks asset and royalty aggregation strategy focuses on optimizing positive future cash flows from an emerging portfolio of licensed products such as Ziihera.

Zymeworks 是一家全球性生物技术公司，管理着一系列授权医疗资产，并开发多样化的新型多功能生物治疗产品管线，旨在改善包括癌症、炎症和自身免疫性疾病在内的难治性疾病的治疗标准。Zymeworks 的资产与特许权使用费整合战略侧重于优化来自 Ziihera 等授权产品新兴组合的未来正向现金流。

®

®

(zanidatamab-hrii) and other licensed products and product candidates, such as pasritamig. In addition, Zymeworks is also building a portfolio of healthcare assets that can generate strong cash flows, while supporting the development of innovative medicines. Zymeworks is rapidly advancing a robust pipeline of product candidates, leveraging its expertise in both antibody drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need.

（zanidatamab-hrii）以及其他授权产品和候选产品，例如 pasritamig。此外，Zymeworks 还在构建一个能够产生强劲现金流并支持创新药物开发的医疗资产组合。Zymeworks 正在快速推进其丰富的候选产品管线，凭借其在抗体偶联药物和针对重大未满足医疗需求领域新通路的多特异性抗体疗法方面的专业知识。

Zymeworks complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutics. These capabilities have been further leveraged through strategic partnerships with global biopharmaceutical companies.

Zymeworks 的互补性治疗平台和完全集成的药物开发引擎提供了灵活性和兼容性，能够精确设计和开发高度差异化的抗体类疗法。这些能力已通过全球生物制药公司的战略合作伙伴关系得到进一步发挥。

For information about Zymeworks, visit .

有关 Zymeworks 的信息，请访问。

www.zymeworks.com

www.zymeworks.com

and follow @ZymeworksInc on X.

并在 X 上关注 @ZymeworksInc。

SOURCE Gandeeva Therapeutics Inc.

来源：Gandeeva Therapeutics Inc.

21

二十一

%

%

more press release views with

更多新闻稿浏览量，通过

Request a Demo

请求演示